|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
M.D. Anderson Cancer Center Genentech |
|---|---|
| Information provided by: | M.D. Anderson Cancer Center |
| ClinicalTrials.gov Identifier: | NCT00081861 |
Purpose
Phase II Study of Avastin Plus Rituximab for Patients with Relapsed and Chemotherapy - or Rituxan Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma.
| Condition | Intervention | Phase |
|---|---|---|
|
Lymphoma |
Drug: Avastin (Bevacizumab) Drug: Rituximab |
Phase II |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study |
| Official Title: | A Phase II Study of Avastin Plus Rituximab for Patients With Relapsed and Chemotherapy- or Rituxan-Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, Texas | |
| UT MD Anderson Cancer Center | |
| Houston, Texas, United States, 77030 | |
| Principal Investigator: | Barbara Pro, MD | U.T. M.D. Anderson Cancer Center |
More Information
| Study ID Numbers: | 2003-0520 |
| Study First Received: | April 23, 2004 |
| Last Updated: | September 17, 2007 |
| ClinicalTrials.gov Identifier: | NCT00081861 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
Non-Hodgkin's Lymphoma B-Cell Lymphoma Lymphoma |
Avastin Bevacizumab Rituximab |
|
Immunoproliferative Disorders Immunologic Factors Rituximab Bevacizumab Angiogenesis Inhibitors Lymphoma, B-Cell Lymphoma, Small Cleaved-cell, Diffuse |
Lymphatic Diseases B-cell Lymphomas Lymphoma, Non-Hodgkin Aggression Lymphoproliferative Disorders Antirheumatic Agents Lymphoma |
|
Neoplasms by Histologic Type Immunoproliferative Disorders Immune System Diseases Immunologic Factors Antineoplastic Agents Rituximab Growth Substances Physiological Effects of Drugs Bevacizumab Angiogenesis Inhibitors Pharmacologic Actions |
Lymphoma, B-Cell Lymphatic Diseases Neoplasms Therapeutic Uses Growth Inhibitors Angiogenesis Modulating Agents Antirheumatic Agents Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Lymphoma |